Article Text

Download PDFPDF

Review: early postnatal corticosteroids reduce chronic lung disease in preterm infants, but increase complications
  1. Anne Major, RGN, RM, Clinical Facilitator
  1. Neonatal Unit Sharoe Green Hospital Preston, Lancashire, UK

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

QUESTIONS: Does early postnatal corticosteroid (PC) treatment given within the first 96 hours of birth decrease the risk of chronic lung disease (CLD) in at risk, preterm infants? Do PCs increase the risk of adverse effects?

Data sources

Studies were identified by searching the Oxford Database of Perinatal Trials, the Cochrane Controlled Trials Register, and Medline (1966 to September 2000); handsearching paediatric and perinatal journals; examining review articles; and contacting practising neonatologists.

Study selection

Randomised controlled trials were selected if they compared intravenous PC treatment given within 96 hours of birth with control (placebo or nothing) in preterm infants at risk of developing CLD.

Data extraction

Data were extracted on study methods, participant characteristics, and outcomes.

Main results

19 trials were included in the analysis. Most trials involved low birthweight infants with respiratory distress syndrome (RDS) who were receiving mechanical ventilation. The most common treatment assessed was dexamethasone, 0.50 mg/kg/day for 3 days, followed by 0.25 mg/kg/day for 3 days, 0.12 mg/kg/day for 3 days, and 0.05 mg/kg/day for 3 days. Meta-analysis showed that early PC treatment reduced CLD and combined death or CLD at 28 days and at 36 weeks postmenstrual age, and need for late steroids; but increased metabolic complications (hyperglycaemia, hypertension, hypertrophic cardiomyopathy, and growth failure) and gastrointestinal complications (gastrointestinal bleeding and intestinal perforation) (table). It did not affect mortality at 28 days (14 studies, n=1637) or before discharge (19 studies, n=2567). Meta-analysis of long term follow up studies showed an increased risk of developmental delay, cerebral palsy, and combined death or cerebral palsy (table).


Early corticosteroid treatment within 96 hours of birth prevents chronic lung disease in at risk, preterm infants, but increases the risk of metabolic and gastrointestinal complications in the short term, and developmental delay and cerebral palsy in the long term.

Early postnatal corticosteroids (PCs) (<96 h after birth) v control in at risk, preterm infants*


The aim of multidisciplinary teams that care for preterm infants in neonatal intensive care units is to reduce the risk of CLD without compromising the short and long term condition of these infants. It is therefore important for clinicians caring for preterm infants to use evidence based treatment regimens that are effective and are evaluated on a regular basis.

Corticosteroids, which are used to reduce persistent inflammation within the lungs, have both short term and long term effects. In 2 separate systematic reviews, Halliday and Ehrenkranz evaluated the evidence available on the use of PCs to reduce CLD and mortality, as well as the implications of short and long term side effects associated with early and moderately early intravenous PCs. Inhaled corticosteroids were not considered in either of these reviews as they were the subject of a separate review.1 19 randomised controlled trials were included in the analysis of early PCs (given within 96 h of birth), whereas only 7 trials were included in the analysis of moderately early PCs (given at 7–14 d after birth).

The reviews concluded that both early and moderately early PCs reduce CLD and the combined outcome of CLD or mortality. Although these benefits are substantial, the reviews also confirm that both early and moderately early PCs increase the risk of short term gastrointestinal and metabolic complications. These complications are clinically significant and present a dilemma to clinicians weighing the risks and benefits of this treatment. Evidence also suggests that early PCs increase the incidence of cerebral palsy and developmental delay. Because this finding is based on only 2 studies,2, 3 further research is needed. Growth is another area of concern for clinicians and parents, and the review suggests early PCs are associated with growth failure. The effect of corticosteroids on growth is another area for further investigation.

It is important for clinicians caring for preterm infants to be aware of the short term adverse effects so that they can manage these conditions appropriately. The authors also emphasised the urgent need for further follow up studies of existing randomised controlled trials of postnatal steroids given at any time after birth. In view of the serious nature of the risks involved, the use of PCs should be reserved for situations where the benefits clearly exceed the risks.



  • Source of funding: no external funding.

  • For correspondence: Professor H L Halliday, Department of Child Health, Queen's University of Belfast, Regional Neonatal Unit, Royal Maternity Hospital, Belfast, Northern Ireland BT12 6BB, UK. Fax +44 (0)289 023 6203. h.halliday{at}